Considerable evidence shows sodium-glucose co-transporter-2 inhibitors have cardioprotective benefits, but new research elucidates the ways in which the drugs can also have positive renal impacts. The ...
In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...
HFSA 2020 Dapagliflozin's CKD Performance Sends Heart Failure Messages The DAPA-CKD trial results have important messages for cardiologists, especially heart failure physicians. Medscape Medical News, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results